<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04058535</url>
  </required_header>
  <id_info>
    <org_study_id>ALT-L9-01</org_study_id>
    <nct_id>NCT04058535</nct_id>
  </id_info>
  <brief_title>Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular Age-related Macular Degeneration</brief_title>
  <official_title>A Phase I Clinical Study of ALT-L9 in Patients With Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alteogen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alteogen, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, efficacy and pharmacokinetics of repeated intravitreal administration
      of ALT-L9 2 mg/50uL compared with Eylea in patients with neovascular Age-related macular
      degeneration.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrences of adverse events</measure>
    <time_frame>8 weeks</time_frame>
    <description>Check the adverse events in study eye at the assessment points after triple administration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>ALT-L9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal injection of ALT-L9 50 ul, every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eylea</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal injection of Eylea 50 ul, every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Eylea</intervention_name>
    <description>Aflibercept</description>
    <arm_group_label>Eylea</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALT-L9</intervention_name>
    <description>Aflibercept biosimilar</description>
    <arm_group_label>ALT-L9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged 50yeras old or more at the time of consent.

          2. Patients with any history of anti-VEGF treatment(Aflibercept, Bevacizumab,
             Ranibizumab) for neovascular AMD in the study eye.

          3. Patients who were treated with the last anti-VEGF at least 8 weeks prior to study drug
             administration.

          4. Patients with untreated active primary subfoveal CNV lesions secondary to AMD,
             including juxtafoveal lesions that affect the fovea as evidenced by FA in the study
             eye at the start of the screening visit.

          5. Patients with subretinal, intraretinal, or subretinal pigment epithelium fluid as
             assessed by SD-OCT in the study eye at the start of the screening visit.

          6. Patients who have CNV which is at least 50% of total lesion size in the study eye at
             the start of the screening visit.

          7. Patients with ETDRS best-corrected visual acuity of 20/40 to 20/320 (letter score of
             73 to 25) in the study eye at the start of the administration of the study drug.

          8. Patients with ETDRS best-corrected visual acuity of 20/400 (letter score 20) or better
             in the fellow eye at the start of the administration of the study drug.

        Exclusion Criteria:

          1. Patients who have received any prior ocular (in the study eye) or systemic treatment
             for neovascular AMD within 8 weeks from the screening date except dietary supplements
             or vitamins.

          2. Patients who have received any surgery for neovascular AMD.

          3. Patients with any current or history of macular or retinal disease other than
             neovascular AMD (eg, diabetic macular edema, retinal vein occlusion, pathological
             myopia, angioid streaks, ocular histoplasmosis, trauma, retinal detachment, epiretinal
             membrane, macular hole, central serous chorioretinopathy, Choroidal rupture, Multiple
             network choroiditis, proliferative diabetic retinopathy) in the study eye.

          4. Patients with scar, fibrosis, or atrophy involving the center of the fovea in the
             study eye that might interfere with visual acuity.

          5. Patients with hemorrhage under the fovea or subretinal hemorrhage 50% or more of the
             total lesion area in the study eye.

          6. Patients with retinal pigment epithelial tears or rips involving the macula in the
             study eye.

          7. Patients with a history of any vitreous hemorrhage or rhegmatogenous retinal
             detachment in the study eye within 4 weeks before the start of the administration of
             the study drug.

          8. Patients who have received panretinal photocoagulation in the study eye.

          9. Patients who have received vitreous surgery in the study eye.

         10. Patients with a history of corneal transplant or corneal dystrophy in the study eye.

         11. Patients who have received cataract surgery or Lasik in the study eye within 90 days
             before the start of the administration of the study drug.

         12. Patients who have received trabeculectomy or other filtration surgery in the study
             eye.

         13. Patients with poorly controlled glaucoma (defined as intraocular pressure â‰¥ 25 mmHg
             despite treatment with antiglaucoma medication) in the study eye.

         14. Patients with significant media opacities, including cataract, in the study eye that
             might interfere with visual acuity, assessment of safety, or fundus photography
             considered by the principal investigator or investigator.

         15. Patients with any diseases in the study eye that could have compromised visual acuity
             such as amblyopia and anterior ischemic optic neuropathy considered by the principal
             investigator or investigator.

         16. Patients with cataract in the study eye that could have required medical or surgical
             intervention during the course of the study considered by the principal investigator
             or investigator.

         17. Patients with aphakia with absence of posterior capsule (in the study eye.

         18. Patients who have received therapeutic radiation in the region of the study eye.

         19. Patients who use topical ocular corticosteroids for 30, or more, consecutive days
             within 90 days before the screening visit, or have a plan or actual use for 30 or more
             consecutive days during the course of the study in the study eye.

             Criteria for fellow eye or either eye:

         20. Patients with any active intraocular or periocular infection or intraocular
             inflammation in either eye (eg, infectious blepharitis, infectious conjunctivitis,
             keratitis, scleritis, endophthalmitis).

         21. Patients with a history of uveitis in either eye.

         22. Patients with a concurrent or history of scleromalacia in either eye.

         23. Patients who have received anti-VEGF medication in the fellow eye within 8 weeks
             before the start of the administration of the study drug.

             Other criteria:

         24. Patients who use systemic corticosteroids for 30 or more consecutive days within 90
             days before the Screening Visit, or have a plan or actual use for 30 or more
             consecutive days during the course of the study. Inhaled steroids were permitted.

         25. Patients who use steroid(except systemic or inhaled steroid) within 6 months, or have
             a plan for use of steroid during the course of the study.

         26. Patients with poorly controlled hypertension. (defined as systolic BP is 160 mmHg or
             more or diastolic BP is 100 mmHg or more despite medication)

         27. Patients with a serious liver, kidney or cardiovascular disorders considered by the
             principal investigator or investigator.

         28. Patients with a concurrent or history of malignancy within 5 years before informed
             consent.

         29. Patients with drug abuse (defined as use of illegal drugs) or alcohol dependence or a
             history of these conditions.

         30. Patients with a history of clinically significant drug hypersensitivity.

         31. Patients with a history of allergy to aflibercept, fluorescein, indocyanine green and
             povidone iodine.

         32. Patients with any contraindications described in aflibercept package insert.

         33. Females who are pregnant, breastfeeding, or of childbearing potential, unwilling to
             practice adequate contraception throughout the study.

         34. Patients with type 1 diabetes or increase of HbA1c(&gt;12%).

         35. Patients who have received any other investigational drug within 12 weeks before
             screening visit.

         36. Other patients considered by the principal investigator or investigator to be
             inappropriate as subjects.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alteogen</name>
      <address>
        <city>Daejeon</city>
        <state>Korea, Republic of(KOR)</state>
        <zip>34054</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 14, 2019</study_first_submitted>
  <study_first_submitted_qc>August 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2019</study_first_posted>
  <last_update_submitted>September 1, 2019</last_update_submitted>
  <last_update_submitted_qc>September 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

